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Identity 
Other names: PPD: CCN6; LIBC; PPAC; Wnt1 
signaling pathway protein 3 




5 exons spanning 967kb of genomic. 
Transcription 
Alternative splicing generates at least three transcript 
variants, their sizes are 1212bp, 1307 bp and 1068 bp. 
Protein 
Description 
WISP3 contains four conserved cysteine-rich  
domains: insulin-like growth factor-binding domain, 
von Willebrand factor type C module, thrombospondin 
domain and C-terminal cystine knot-like domain. It has 
three isoforms: 1) variant 1, 354 aa, 39292 Da; 2) 
variant 2, 331 aa, This variant differs from variant 1 in 
two regions. It has an alternate 5' end which results in a 
different N-terminus.  
It also uses two alternative donor and acceptor sites in 
the middle coding region which result in a few inter al 
aa differences between variant 1 and 2. 3) variant 3, 
372 aa, This variant differs in the 5' UTR and CDS, 
compared to variant 1.  
The resulting protein is longer and has a distinct N-
terminus, compared to variant 1. 
Expression 
Predominant expression in adult kidney and testis and 
fetal kidney. Weaker expression found in placenta, 
ovary, prostate and small intestine. Also expressed in 
skeletally-derived cells such as synoviocytes and 

















It is a member of the WNT1 inducible signaling 
pathway (WISP) protein subfamily, which belongs to  
the connective tissue growth factor (CTGF) family and 
may be downstream in the WNT1 signaling pathway 
that is relevant to malignant transformation. It is over-
expressed in colon tumors. It is essential for normal 
postnatal skeletal growth and cartilage homeostasis. It 
acts as a putative growth regulator contributing to the 
inflammatory breast cancer by regulating tumor cell 
growth, invasion and angiogenesis. 
Homology 
Wnt1-inducible signaling proteins. 
Mutations 
Germinal 
Various types of mutations have been described, 
dispersed throughout the gene, including nucleotide 
substitutions, small deletions and small insertions. 
There are patients who are compound heterozygous, 
heterozygous or homozygous. The mutations cause 
progressive pseudorheumatoid dysplasia. 
Somatic 
Somatic mutations that cause reading frameshifts at a
polyadenosine tract within the WISP3 coding sequence 
have been observed at higher-than-expected rates in 
gastrointestinal tumors from patients with mutations i  
the mismatch repair pathway. 
Implicated in 
Arthropathy, progressive 
pseudorheumatoid, of childhood 
Disease 
Mutations in the WISP3 gene result in an arthropathy 
of childhood beginning at about age 3-8. Usually 
several joints were affected with pain and soft tissue 
swelling. The proximal interphalangeal joints of the 
hand were most commonly affected and the hips and 
elbows next most often involved. 
Inflammatory breast cancer 
Oncogenesis 
Loss of WISP3 is one of the key genetic alterations in 







Frameshifts, non-sense mutations and non-synonymous 
changes involving cysteines or affect a splice-donor 
site. 
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